| Autor: |
Shanko A; Research and Development Department, FORT LLC, 119435 Moscow, Russia.; N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology, Ivanovsky Institute of Virology, 123098 Moscow, Russia., Shuklina M; WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia., Kovaleva A; WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia., Zabrodskaya Y; WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia.; Peter the Great Saint-Petersburg Polytechnical University, 194064 Saint-Petersburg, Russia.; Petersburg Nuclear Physics Institute named by B. P. Konstantinov of National Research Center 'Kurchatov Institute', 188300 Gatchina, Russia., Vidyaeva I; WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia., Shaldzhyan A; WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia., Fadeev A; WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia., Korotkov A; WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia., Zaitceva M; WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia., Stepanova L; WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia., Tsybalova L; WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia., Kordyukova L; Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119991 Moscow, Russia., Katlinski A; Board Member, FORT LLC, 119435 Moscow, Russia. |
| Abstrakt: |
A series of commercial inactivated influenza vaccines (IIVs) used in the Russian National Immunization Program were characterized to evaluate their protective properties on an animal model. Standard methods for quantifying immune response, such as hemagglutination inhibition (HAI) assay and virus neutralization (VN) assay, allowed us to distinguish the immunogenic effect of various IIVs from that of placebo. However, these standard approaches are not suitable to determine the role of various vaccine components in immune response maturation. The expanded methodological base including an enzyme-linked immunosorbent assay (ELISA) and a neuraminidase ELISA (NA-ELISA) helped us to get wider characteristics and identify the effectiveness of various commercial vaccines depending on the antigen content. Investigations conducted showed that among the IIVs tested, Ultrix ®, Ultrix ® Quadri and VAXIGRIP ® elicit the most balanced immune response, including a good NA response. For Ultrix ® , Ultrix ® Quadri, and SOVIGRIPP ® (FORT LLC), the whole-virus specific antibody subclass IgG1, measured in ELISA, seriously prevailed over IgG2a, while, for VAXIGRIP ® and SOVIGRIPP ® (NPO Microgen JSC) preparations, the calculated IgG1/IgG2a ratio was close to 1. So, the immune response varied drastically across different commercial IIVs injected in mice. |
